Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

@article{Coombes2007SurvivalAS,
  title={Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial},
  author={R. Charles Coombes and L S Kilburn and CF Snowdon and Robert J Paridaens and R. E. Coleman and SE Jones and Jacek Jassem and Cjh van de Velde and Thierry Delozier and Isabel {\'A}lvarez and Lucia Del Mastro and Olaf Ortmann and Klaus Diedrich and A. S. Coates and Emilio Bajetta and SB Holmberg and D. J. Dodwell and Elizabeth Mickiewicz and J{\o}rn Andersen and Per Eystein L{\o}nning and Giorgio Cocconi and John F. Forbes and Monica Castiglione and N Stuart and Alan L. Stewart and L. J. Fallowfield and Gianfilippo Bertelli and Emily Hall and R. H. Bogle and Marina Carpentieri and Elena Colajori and Milayna Subar and Elizabeth Ireland and JM Bliss},
  journal={The Lancet},
  year={2007},
  volume={369},
  pages={559-570}
}
Phase III randomized adjuvant study of tamoxifen alone versus sequential tamoxifen and anastrozole in Japanese postmenopausal women with hormone-responsive breast cancer: N-SAS BC03 study
TLDR
Switching from tamoxifen to anastrozole was likely to decrease disease recurrence in postmenopausal Japanese breast cancer patients and Ethnic differences in major adverse events may be attributable to a low baseline risk of these events in Japanese.
Benefit from exemestane as extended adjuvant therapy after 5 years of adjuvant tamoxifen: intention-to-treat analysis of the National Surgical Adjuvant Breast And Bowel Project B-33 trial.
TLDR
Original exemestane assignment resulted in non-statistically significant improvement in DFS and in statisticallysignificant improvement in RFS, and toxicity, assessed up to time of unblinding, was acceptable for the adjuvant setting.
Long-term endometrial effects in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES)—a randomised controlled trial of exemestane versus continued tamoxifen after 2–3 years tamoxifen
  • G. Bertelli, E. Hall, J. Bliss
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2010
TLDR
Switching from tamoxifen to exemestane significantly reverses endometrial thickening associated with continued tamoxIfen, and may have partial estrogen-like effects on the postmenopausal uterus.
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial.
TLDR
Switching to anastrozole after the first 2-3 years of treatment was confirmed to improve event-free and relapse-free survival of postmenopausal, node-positive, ER-positive early breast cancer patients already receiving adjuvant tamoxifen.
To switch or not to switch: should the updated Intergroup Exemestane Study alter our decision?
TLDR
Switching to exemestane for patients who have already had tamoxifen therapy for 2–3 years would appear to be an appropriate strategy for the majority of early breast cancer patients, and an overall survival advantage for switching is shown.
Tamoxifen and anastrozole as a sequencing strategy: a randomized controlled trial in postmenopausal patients with endocrine-responsive early breast cancer from the Austrian Breast and Colorectal Cancer Study Group.
  • P. Dubsky, R. Jakesz, M. Gnant
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
Despite a low overall rate of recurrence in a population with breast cancer at limited risk of relapse, the a priori sequence strategy of 2 years of TAM followed by 3 years of ANA led to small outcome and toxicity benefits.
Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group.
TLDR
Exemestane is an effective and well-tolerated first-line hormonal treatment for postmenopausal women with MBC and offers significant early improvement in time to tumor progression when compared with tamoxifen.
Randomized trial of tamoxifen versus combined tamoxifen and octreotide LAR Therapy in the adjuvant treatment of early-stage breast cancer in postmenopausal women: NCIC CTG MA.14.
  • K. Pritchard, L. Shepherd, M. Pollak
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2011
TLDR
Whether octreotide would lower insulin and IGF-1 levels and reduce risk of breast cancer recurrence andOctreotide did not add significant clinical benefit and high C-peptide levels and high BMI were associated with poor outcome.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 22 REFERENCES
Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
TLDR
Letrozole after tamoxifen is well-tolerated and improves both disease- free and distant disease-free survival but not overall survival, except in node-positive patients.
Mature results of a randomized phase II multicenter study of exemestane versus tamoxifen as first-line hormone therapy for postmenopausal women with metastatic breast cancer.
TLDR
Exemestane is well tolerated and active in the first-line treatment of hormone-responsive MBC, and an ongoing EORTC phase III trial is comparing the efficacy, measuring time-to-disease progression, of exemstane and tamoxifen.
A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.
TLDR
Exemestane therapy after two to three years ofTamoxifen therapy significantly improved disease-free survival as compared with the standard five years of tamoxIFen treatment.
Anastrozole Is Superior to Tamoxifen as First-Line Therapy in Hormone Receptor Positive Advanced Breast Carcinoma Results of Two Randomized Trials Designed for Combined Analysis
TLDR
In postmenopausal women with hormonally sensitive ABC, anastrozole should be considered as the new standard first-line treatment, and tamoxifen was well tolerated.
Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial.
TLDR
Switching to anastrozole after the first 2 to 3 years of treatment is well tolerated and significantly improves event-free and recurrence-free survival in postmenopausal patients with early breast cancer.
Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group.
TLDR
Letrozole was significantly superior to tamoxifen in TTP, TTF, ORR, and clinical benefit rate, and its results support its use as first-line endocrine therapy in postmenopausal women with advanced breast cancer.
Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98.
TLDR
The present updated analysis, which was limited to patients on monotherapy arms in BIG 1-98, yields results similar to those from the previous primary analysis but more directly comparable with results from other trials of continuous therapy using a single endocrine agent.
Anastrozole Versus Tamoxifen as First-Line Therapy in Postmenopausal Patients With Hormone-Dependent Advanced Breast Cancer: A Prospective, Randomized, Phase III Study
TLDR
Anastrozole showed significant advantages over tamoxifen for CB, median TTP in patients gaining CB, and survival, and these data further support routine use of anastroZole as first-line treatment for postmenopausal hormone-dependent ABC.
...
1
2
3
...